HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens - Wikidata - awgldk - TriplyDB

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens

http://www.wikidata.org/entity/Q33711632

about

Status quo and development trend of breast biopsy technology Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method Testing for her2 in breast cancer: current pathology challenges faced in Canada.Practical implications of gene-expression-based assays for breast oncologists.A simple and reproducible prognostic index in luminal ER-positive breast cancers Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study.Whole slide imaging for human epidermal growth factor receptor 2 immunohistochemistry interpretation: Accuracy, Precision, and reproducibility studies for digital manual and paired glass slide manual interpretation.Problems In Determining Her2 Status In Breast Carcinoma.Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma.Are biopsy specimens predictive of HER2 status in gastric cancer patients?Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer.Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).The Core Needle and Surgical Biopsy Concordance to Detect Estrogen, Progesterone, and Her-2 Receptors in Breast Cancer: A Comparative Study.

P2860

Q27006722-03341B90-C78D-4C46-96E4-DD912685C197 Q28535362-3316D4DD-B39C-4C62-A1B2-0C78E24D222E Q36416223-DDBF7DC5-C368-4426-9DD0-9F390BC6505C Q36989546-6556B73E-3F75-49AF-9EB8-D757A1A98180 Q37126908-ADF07848-B122-4F75-BDEC-76DB813A5DB3 Q38395457-601F1F55-04DC-43BA-9F91-20EF0B98355B Q40291272-932BC99A-B98C-4552-ABAE-1909F0EBE45F Q42316292-9A639462-BD55-47BD-88BB-4E01A1616E3D Q44663445-138014FE-E73E-41F9-B604-2157D38FB053 Q44885327-34681A88-CE62-44CA-A7D3-CE1A2A72FCAD Q50198110-8E0DE8D4-215F-43A9-9F27-0B43A417FE6C Q50891158-9411B8EE-5BBA-443C-A35B-1D766B221735 Q51663878-A22D2B77-7D21-4929-B566-EF4F9560FABB Q54538229-3F496CF5-3B1B-4F70-85E3-FBBAFAEC43E8 Q55423379-FE75F40C-965C-4231-9483-53F2B2519BDD

P2860

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens

http://www.wikidata.org/entity/Q33711632

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

HER2 testing on core needle bi ...... surgically resected specimens

@ast

HER2 testing on core needle bi ...... surgically resected specimens

@en

type

label

HER2 testing on core needle bi ...... surgically resected specimens

@ast

HER2 testing on core needle bi ...... surgically resected specimens

@en

prefLabel

HER2 testing on core needle bi ...... surgically resected specimens

@ast

HER2 testing on core needle bi ...... surgically resected specimens

@en

P1433

Q33711632-4B5C57F8-6000-4D60-A5CA-8915238DFD70

P1476

Q33711632-50B521E3-565F-403C-BB7E-8E30349ECDAF

P2093

Q33711632-2EE84D3A-CA41-44C6-AB18-529118C29CB0

Q33711632-3FA214C2-6E9D-4EA6-A9A4-BED4E51E7139

Q33711632-6609CF66-E389-4128-B237-A465FEFF9B56

Q33711632-8BFA9400-CCAB-4919-B248-3980C49B4676

Q33711632-9A0DDA50-832E-4881-8173-8FD513D0CBCE

Q33711632-E982DBB1-E9D5-4F77-97F4-0B9B39A94501

P2860

Q33711632-108BBD15-FC88-4745-BB41-33E6D7149FF7

Q33711632-14E78B67-B1D6-479A-825A-E3AA522933F2

Q33711632-17810D72-C2CE-4698-9868-6EC69DA09E73

Q33711632-1CB8F7E1-07CA-4A68-9518-CB31FCC5B14D

Q33711632-27E27E69-13B6-4682-894D-98113BA091E9

Q33711632-2B0783F9-D2A5-4063-865E-7A4FDCC1884A

Q33711632-2DDC1689-EA2F-4C71-9C7E-F5AC79440013

Q33711632-2F7ACAAA-3A79-4D6C-9F17-0F3BAD3A2153

Q33711632-31DFBD04-4688-4A36-8521-FB5D126D45EA

Q33711632-366CF9B1-EE07-4B83-8F5F-D4DE8BDB08F6

P2888

Q33711632-47BAD5B6-418C-4391-85A8-4373E2D9C848

P304

Q33711632-2226645F-6410-4248-A4AC-CDBA5198EDAB

P31

Q33711632-685F8B27-08C2-4208-862E-5874D045A8FD

P356

Q33711632-910E3B32-1B88-498D-B019-5216A968D92B

P407

Q33711632-15F648B0-6ABB-464A-B1A8-D9C380EC5A6B

P478

Q33711632-04BD0522-0C59-424B-8625-4A2F731F0942

P577

Q33711632-27BC5B8E-6680-4638-8B07-466A373DFAF3

P5875

Q33711632-1C7EE369-F4E8-4FA9-811F-6AAC3DC524DA

P6179

Q33711632-D7927DB6-06A4-413F-9348-A687DB53835F

P698

Q33711632-65F7695F-5FC6-4D06-BBDD-3FC5B25A1AE4

P921

Q33711632-A7876C12-BF3E-4DF0-9897-4B1CAC6015FD

P932

Q33711632-46FC5C35-0690-4F9C-B2A8-73B5062183C9

P356

1471-2407-10-534

P1433

P1476

HER2 testing on core needle bi ...... surgically resected specimens

@en

P2093

Hitoshi Tsuda

http://www.w3.org/2001/XMLSchema#string

Masafumi Kurosumi

http://www.w3.org/2001/XMLSchema#string

Robert Yoshiyuki Osamura

http://www.w3.org/2001/XMLSchema#string

Shinobu Umemura

http://www.w3.org/2001/XMLSchema#string

Sohei Yamamoto

http://www.w3.org/2001/XMLSchema#string

Takayuki Kobayashi

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.

Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

P2888

1471-2407-10-534

P304

534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-10-534

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47356805

http://www.w3.org/2001/XMLSchema#string

P6179

1023809873

http://www.w3.org/2001/XMLSchema#string

P698

20925963

http://www.w3.org/2001/XMLSchema#string

P921

reproducibility

P932

2958945

http://www.w3.org/2001/XMLSchema#string